Proteros
Business Services · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Bunsenstr. 7a, Martinsried, Bavaria, 821...Phone Number
+49 897007610Website
www.proteros.comRevenue
$21 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Proteros
Proteros is a privately held early-stage drug discovery services provider committed to helping pharmaceutical and biotech companies unlock even the most challenging drug targets. Proteros pioneered the industrialization of structural biology, and has developed a cutting-edge drug discovery platform that encompasses protein sciences, protein crystallography and cryo-EM, assays, biophysics and screening, positioned to open the door to lead optimization and clinical programs for technically demanding targets. The company works continuously with most of the world's largest pharma companies and its global client base.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Proteros your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Proteros has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Proteros
Check out if Proteros is spiking on competitors!
Funding: Get notified immidiatlly once Proteros has new funding data
Proteros, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Proteros recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Proteros had a recent Job posting/layoffs
Product Launch: Get notified when Proteros launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Proteros is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Proteros is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Proteros.
Proteros Tech Stack
A closer look at the technologies used by Proteros
Most Recent Scoops
Hiring Plans
Proteros has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Proteros has more open roles in Human Resources than it has had at any time in the past 9 months.
Hiring Plans
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Proteros News & Media
Proteros receives minority investment from private equity firm Inflexion
MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH, a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding. The transaction is subject to customary regulatory approvals and is expected tAdrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases
CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH (Munich, Germany) to accelerate the discovery of first-in-class candidate drugs for intractable diseases. “Throughout my career I’ve watched our industry design candidate drugs for targets that turned out to be inadequatelyProteros Expands Oncology Collaboration and License Agreement with AstraZeneca
MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein. UProteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer. The collaboration brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with AstraZeneca’s expertise in target biology and medicinal chemistry to jointly discove
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Proteros
Sign Up For FreeTo access detailed company insights
Proteros is a privately held early-stage drug discovery services provider committed to helping pharmaceutical and biotech companies unlock even the most challenging drug targets. Proteros pioneered the industrialization of structural biology, and has developed a cutting-edge drug discovery platform that encompasses protein sciences, protein crystal... Read More
